PATENT CLAIM ANALYSIS

Application Number: 16034558
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2019-03
Patent Classification: ["546", "158000"]

Abstract:
The invention relates generally to novel EPAC1 activators, such as Formula I and the preparation thereof as well as the use of EPAC1 activators as human immunodeficiency virus (HIV) latency reversal agents (LRAs).

Claim (Index 8):
The compound of  claim 1 , wherein R 3  is \u03b4-Lactam, wherein the 4, 5-ring carbons of the lactam ring is fused with the aryl group of Formula I.

Metadata:
- Claim Count in Document: 12.0
- Percentile: 95.0
- Lexical Diversity: 1.25806
- Patent Class: 546.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['13640732', '15847628', '14371075', '15313286', '15110000']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7630831958884141
- 35 USC 102 Novelty (BERT): 0.5133786435030955
- Combined Prediction Score: 0.7381127406498822
- Mean Citation Score: 261.35323200000005
- Max Citation Score: 266.34564
- Similarity Product: 180.57252578757763

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test